AI Article Synopsis
Article Abstract
Objectives: Bioprostheses with pericardial leaflets mounted externally on the stent pose a high risk for valve-in-valve (ViV) procedures. This study analyzed the efficacy and safety of ViV procedures for treating structural valve deterioration (SVD) in Mitroflow bioprostheses.
Methods: Between January 2012 and August 2017, 11 patients (mean age 80.3 ± 5.6 years) were treated for SVD of Mitroflow bioprostheses with transcatheter ViV procedures (six transapical [TA] and five transfemoral [TF]) using balloon expandable bioprostheses.
Results: All patients but one were in NYHA class III-IV. Mean STS PROM, euroSCORE I, and euroSCORE II were 8 ± 6.5%, 27.8 ± 11.5%, and 12 ± 5.9%, respectively. Two patients had a "porcelain aorta." The size of implanted valves were 23 mm in 10 cases and 26 mm in one case. One patient suffered a coronary occlusion during a TF approach. The mean volume of contrast used in TF implants was 163 ± 69.8 mL. No contrast media were used in TA procedures. There was one in-hospital death (10%). At 1 year of follow-up, peak and mean aortic gradients were 25.5 ± 5.8 mmHg and 15.5 ± 5.7 mmHg, respectively. One patient had mild paravalvular regurgitation. Cumulative survival was 90.9% at 1 year, 70.7% at 2 years, and 53% at 3 years.
Conclusions: ViV procedures with balloon-expandable aortic valves provide good hemodynamic and clinical mid-term results for treating patients with a degenerated Mitroflow aortic bioprosthesis. Special care must be taken in small aortic roots, when the stented valve is in the supra-annular position to avoid coronary ostial obstruction.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/jocs.13720 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Balloon-assisted bioprosthetic or native aortic scallop intentional laceration to prevent iatrogenic coronary artery obstruction with en face view for patients exhibiting severe calcified leaflet: a case report.
Eur Heart J Case Rep
December 2024
Department of Cardiology, Sendai Kousei Hospital, 1-20, Tsutsumidori Amamiya-cho, Aoba-ku, Sendai, Miyagi 981-0914, Japan.
Background: Balloon-assisted bioprosthetic or native aortic scallop intentional laceration to prevent iatrogenic coronary artery obstruction (BA-BASILICA) enables valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) in patients at risk of coronary artery obstruction. However, its efficacy in patients with severely calcified leaflets remains unclear.
Case Summary: We report a 78-year-old woman with a deteriorated 21 mm Carpentier-Edwards PERIMOUNT Magna valve.
Multicenter Evaluation of Machine-Learning Continuous Pulse Rate Algorithm on Wrist-Worn Device.
Digit Biomark
December 2024
Empatica Srl, Milan, Italy.
Introduction: Though wrist-worn photoplethysmography (PPG) sensors play an important role in long-term and continuous heart rhythm monitoring, signals measured at the wrist are contaminated by more intense motion artifacts compared to other body locations. Machine learning (ML)-based algorithms can improve long-term pulse rate (PR) tracking but are associated with more stringent regulatory requirements when intended for clinical use. This study aimed to evaluate the accuracy of a digital health technology using wrist-worn PPG sensors and an ML-based algorithm to measure PR continuously.
View Article and Find Full Text PDFYearly Trends and In-Hospital Outcomes of Patients Undergoing Transcatheter Mitral Valve-In-Valve Replacement in Prosthetic Valve Dysfunction.
Catheter Cardiovasc Interv
December 2024
Division of Cardiology, Rush University Medical Center, Chicago, Illinois, USA.
Introduction: Transcatheter mitral valve-in-valve replacement (TMVR ViV) is becoming a favorable, less invasive procedure among high-risk patients to manage mitral valve dysfunction. We aimed to investigate the trends of the predictors and outcomes of the procedure.
Methods: The national inpatient sample databases of 2016-2020 were analyzed using STATA 17 software and ICD-10 codes for TMVR ViV, with stratification for mitral stenosis (MS) or Mitral regurgitation (MR) as etiology for prosthetic valve dysfunction.
Peri-procedural outcome according to VARC-3 criteria and hemodynamic mid-term follow-up after Valve-in-valve transcatheter aortic valve replacement for failed aortic bioprosthesis.
Cardiovasc Interv Ther
November 2024
Department of Cardiac Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan.
Despite the widespread adoption of valve-in-valve transcatheter aortic valve replacement (VIV-TAVR) for patients with failed aortic bioprosthesis, the effectiveness of this treatment for Japanese patients frequently associated with small aortic annuli remains unclear. From December-2011 to October-2022, 41 consecutive patients undergoing VIV-TAVR were enrolled in this study. The endpoints were technical success, device success, early safety, and two-year mortality according to implanted surgical valve size (small valves: 19-mm and 21-mm, n = 23; large valves: 23-mm and 25-mm, n = 18).
View Article and Find Full Text PDFEffects of Bioprosthetic Valve Fracturing on Valve-in-Valve Transcatheter Aortic Valve Implantation Transvalvular Gradients.
Tex Heart Inst J
November 2024
Department of Cardiovascular Medicine, Kettering Health, Kettering, Ohio.
Article Synopsis
- Valve-in-valve (ViV) transcatheter aortic valve implantation (TAVI) is a new standard treatment for patients with degenerated bioprosthetic valves, but it can lead to patient-prosthesis mismatch affecting survival.
- This study analyzed the safety and effectiveness of bioprosthetic valve fractures in 25 patients who underwent ViV-TAVI between 2015 and 2022, using echocardiograms to evaluate valve function before and after the procedure.
- Results showed significant reductions in both peak and mean transvalvular gradients after fracturing, indicating it is a potential solution for improving outcomes in patients with high gradients or mismatch concerns.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!